Mark Robson, 56, became obsessed with gambling after taking the dopamine agonist drug
to control the symptoms of Parkinson's.
As part of the agreement, Boehringer Ingelheim obtains global development and commercialisation rights to ZP2929, Zealand Pharma's lead glucagon/GLP-1 dual agonist drug
The GLP-1 receptor agonist drug
class - including Novo Nordisk's Victoza and Amylin/Alkermes's Bydureon - is forecasted to earn the second highest sales in the market over the next five years.
s Maxalt-MLT(R), a leading, approved, migraine treatment, based on Rizatriptan, a 5-HT1 receptor agonist drug
Food and Drug Administration to restrict the availability of GlaxoSmithKline's Avandia in the United States and a ruling by the European Medicines Agency to withdraw the drug in Europe will cause Avandia to lose almost all its sales, leaving Takeda's Actos as the predominant representative of the PPAR-gamma agonist drug
class on the market.
LOS ANGELES -- ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug
, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.
2 Percentage of patients who receive the adrenergic receptor agonist drug
clonidine for the treatment of Hypertension
The first GLP1 agonist drug
, Exenatide (Byetta), was approved in 2005, and has already reached sales of over $670 million.
NYSE Amex: PTN) today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug
candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD).
In conjunction with the data presentation, Idera announced the selection of this compound as its lead TLR7/TLR8 agonist drug
candidate for the treatment of hematological malignancies.
The new Pharmacor report entitled Parkinson's Disease finds that the majority of market sales will continue to be driven by the dopamine agonist drug
class that includes Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol, GlaxoSmithKline's Requip, GlaxoSmithKline/SkyePharma's Requip XL/LP/RP/Modutab and UCB/Schwarz Pharma's Neupro.
I am particularly interested in the pace of development of Synergy's GC-C receptor agonist drug
SP-304 to treat GI disorders which is poised to move forward in the clinic in early 2010.